Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Program for Assessment of Capecitabine (Xeloda) Plus Docetaxel First-line Therapies in HER2-negative Metastatic Breast Cancer (XEBRA Study)

NCT01777945 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01777945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01777945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Program for Assessment of Capecitabine (Xeloda) Plus Docetaxel First-line Therapies in HER2-negative Metastatic Breast Cancer (XEBRA Study)
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
December 31, 2012
Completion date
December 31, 2014
Enrollment
46 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer